Qyuns is developing a series of antibody drugs targeting autoimmune and allergic diseases. We are willing to collaborate with potential partners who plans to set foot in the field of autoimmune and allergic diseases, and have the corresponding resources or advantages, to develop our drug candidates or expand their indications, and jointly promote commercialization.

In order to further leverage the value of pipeline drugs and maximize the commercial potential of them, we plan to authorize the pipeline drugs in whole, or by region or indication, to our partners. We believe that relevant strategic cooperation can improve the accessibility of our drug candidates in the fastest and most cost-effective way.

We are also considering sales collaboration with partners who have strong sales channels for autoimmune or allergic diseases, to jointly promote commercialization in relevant fields and exploit market opportunities as widely as possible.